CLINDAMYCIN PHOSPHATE AND TRETINOIN
Clinical safety rating: avoid
No significant drug interactions Highly teratogenic and can cause severe skin irritation.
Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. Tretinoin is a retinoid that binds to retinoic acid receptors (RARs) to normalize follicular keratinization and reduce microcomedone formation.
| Metabolism | Clindamycin phosphate is hydrolyzed to active clindamycin; clindamycin is metabolized primarily by CYP3A4. Tretinoin undergoes hepatic metabolism via CYP450 enzymes. |
| Excretion | Clindamycin phosphate is hydrolyzed to clindamycin; clindamycin and its metabolites are primarily excreted via bile and feces (approximately 85%), with renal excretion accounting for about 10% of the dose. Tretinoin undergoes hepatic metabolism and is excreted in bile and urine as metabolites; less than 1% is excreted unchanged. |
| Half-life | Clindamycin has a terminal elimination half-life of approximately 2-3 hours in adults with normal renal function; may be prolonged in hepatic impairment. Tretinoin has a terminal half-life of approximately 0.5-2 hours following topical application, reflecting rapid cutaneous metabolism. |
| Protein binding | Clindamycin: Approximately 93-94% bound to serum proteins, primarily albumin. Tretinoin: >95% bound to plasma proteins, including albumin and retinol-binding protein. |
| Volume of Distribution | Clindamycin: Vd approximately 0.6-1.2 L/kg, indicating extensive tissue distribution. Tretinoin: Vd is not well characterized for topical application; systemically, it distributes widely but is not clinically relevant for topical use. |
| Bioavailability | Topical clindamycin/tretinoin: Minimal systemic absorption; approximately 0.5-5% of clindamycin and <2% of tretinoin is absorbed through intact skin, resulting in negligible systemic bioavailability. |
| Onset of Action | Topical clindamycin/tretinoin: Clinical improvement in acne vulgaris typically begins within 2-4 weeks of regular application; however, initial worsening may occur during the first few weeks due to tretinoin-induced purging. |
| Duration of Action | Duration of action for topical clindamycin/tretinoin is approximately 24 hours, supporting once-daily application. Sustained effect requires continued application; discontinuation may lead to recurrence of acne lesions. |
| Molecular Weight | Clindamycin phosphate: 505.96 Da; Tretinoin: 300.44 Da. |
Apply a thin layer of the gel (containing clindamycin 1% and tretinoin 0.025%) to the entire face once daily at bedtime.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients below 12 years of age. For children 12 years and older, use same as adult dosing. |
| Geriatric use | No specific dosage adjustment required; use caution due to increased risk of skin irritation in elderly patients with fragile skin. |
| 1st trimester | Topical clindamycin/tretinoin is not recommended in the first trimester due to potential teratogenic effects from retinoids; systemic absorption of clindamycin is low but tretinoin is contraindicated. |
| 2nd trimester | Use with caution; topical application may be considered if benefit outweighs risk, as systemic exposure to both drugs is minimal. Tretinoin is still generally avoided due to retinoid concerns. |
| 3rd trimester | Use only if clearly needed; avoid large areas or prolonged use. Tretinoin is contraindicated in pregnancy due to retinoid toxicity; clindamycin is considered safe topically. |
Clinical note
No significant drug interactions Highly teratogenic and can cause severe skin irritation.
| FDA category | Contraindicated |
| Placental transfer | Clindamycin: crosses placenta and achieves therapeutic levels in fetal serum (approximately 50% maternal levels). Tretinoin: systemic absorption from topical use is minimal, but oral tretinoin is teratogenic; potential for transfer exists if significant absorption occurs. |
■ FDA Black Box Warning
None
| Common Effects | Skin dryness |
| Serious Effects |
Pregnancy (tretinoin component)Hypersensitivity to any componentUse on eczematous or sunburned skin (increased absorption risk)Acute inflammatory skin conditions (relative, but absolute if severe)
| Precautions | Colitis: Clindamycin may cause pseudomembranous colitis; discontinue if diarrhea occurs., Skin irritation: Tretinoin may cause erythema, peeling, or burning; reduce frequency or discontinue if severe., Sun sensitivity: Tretinoin increases photosensitivity; advise sun protection., Pregnancy: Tretinoin is teratogenic; avoid in pregnancy (FDA Category C for topical). |
| Food/Dietary | No significant food-drug interactions. However, ingestion of tretinoin systemic formulations may interact with vitamin A supplements (risk of hypervitaminosis A); topical application has minimal systemic absorption. Clindamycin: no food interactions reported. |
Loading safety data…
| Breastfeeding | Topical clindamycin/tretinoin is considered compatible with breastfeeding if applied to small areas and not to the breast; systemic absorption is low. However, tretinoin's safety is not established; avoid application to the breast and limit use. |
| Lactation Rating | L3 (Moderately Safe) for topical use; avoid if applied to large areas or broken skin. |
| Teratogenic Risk | Pregnancy category C. Tretinoin is a retinoid with known teratogenic potential when absorbed systemically. Topical application results in minimal absorption (<5%), but first-trimester use is contraindicated due to risk of fetal retinoid syndrome (CNS, cardiac, craniofacial defects). Clindamycin phosphate has low systemic absorption and is considered safe topically. Avoid during second and third trimesters unless clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Advise against concurrent oral retinoids. Monitor for local skin reactions. |
| Fertility Effects | No known adverse effects on fertility from topical use. Systemic tretinoin may affect spermatogenesis at high doses, but topical application is unlikely to impact fertility. |
| Clinical Pearls | Apply a pea-sized amount to entire face once daily in the evening. Use a gentle cleanser and moisturizer; avoid waxing, dermabrasion, or laser treatments during therapy. Advise sun protection; may cause photosensitivity. Combination product for acne vulgaris; clindamycin is an antibiotic (risk of pseudomembranous colitis) and tretinoin is a retinoid (teratogenic, use effective contraception). Onset of effect: 2–6 weeks; peak improvement: 8–12 weeks. Do not apply to broken, eczematous, or sunburned skin. |
| Patient Advice | Apply once daily at bedtime to clean, dry skin. · Use a pea-sized amount (about 1/4 inch) to cover the entire face. · Avoid contact with eyes, lips, nostrils, and mucous membranes. · Expect initial worsening of acne (purging) for the first 2–4 weeks. · Use sunscreen daily (SPF 30+) and avoid prolonged sun exposure. · Do not use other topical acne products without consulting your doctor. · Stop use and contact doctor if severe diarrhea (watery or bloody) occurs. · Avoid waxing, electrolysis, or chemical depilatories during treatment. · Do not use if pregnant, planning pregnancy, or breastfeeding. · Store at room temperature, do not freeze. |